Introduction GLP‑1 receptor agonists (semaglutide brands Ozempic and Wegovy, and the GIP/GLP‑1 agent tirzepatide branded Zepbound) are effective tools for blood‑sugar control and weight management — but they commonly cause gastrointestinal side effects during dose initiation and escalation. Knowing what to expect week by week, practical ways to reduce symptoms, and the warning signs that require medical care will help you stay safe and get the benefit of therapy. This guide summarizes dosing patterns, timelines for typical side effects, stepwise self‑care strategies, and clear “red flags” based on FDA product information and clinical guidance. (dailymed.nlm.nih.gov)

How these drugs are started (brief) - Wegovy (semaglutide for chronic weight management) uses a slow 5‑step escalation: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg once weekly, each step generally 4 weeks, reaching maintenance around week 16. Slower walking back on or pausing titration is allowed if side effects occur. (novonordisk.ca)
- Ozempic (semaglutide for diabetes; sometimes used off‑label/different doses for weight) typically starts 0.25 mg once weekly for 4 weeks, then 0.5 mg, with further increases possible after at least 4 weeks. (dailymed.nlm.nih.gov)
- Zepbound (tirzepatide for weight management) usually starts 2.5 mg weekly for 4 weeks; doses are increased in 2.5 mg increments after at least 4 weeks if tolerated. Providers may pause or slow escalation when needed. (accessdata.fda.gov)

The typical side‑effect timeline: what to expect, week by week Weeks –1 to 0: preparation - Before the first injection, discuss medical history (personal/family history of medullary thyroid carcinoma or MEN2 — these are contraindications), recent pancreatitis, gallbladder disease, kidney problems, and current diabetes medications (insulin or sulfonylureas may require dose adjustment). Have a plan with your prescriber for when to hold, slow, or stop dosing. (accessdata.fda.gov)

Weeks 1–4 (first dose window) - What often happens: nausea is the most common initial symptom and is most intense during the first few weeks; vomiting, early satiety, and abdominal discomfort are also common. Clinical trials and labels show GI adverse events cluster around initiation and dose increases. Many people notice improvement as the body adapts. (ncbi.nlm.nih.gov)
- Practical tips for this period: eat smaller portions, favor bland/low‑fat foods, avoid large high‑fat meals, sip clear fluids to prevent dehydration, and eat slowly. Ginger, peppermint tea, and small bland snacks can help. If nausea is moderate, temporary use of an antiemetic under clinician direction (short courses only) may be considered. (doi.org)

Weeks 5–12 (first dose increase(s)) - Expect another cluster of symptoms each time you increase dose. For semaglutide escalations (e.g., going from 0.5 → 1.0 mg or 1.7 → 2.4 mg) many people report a transient increase in nausea or constipation; most tolerate it within days–weeks if escalation is paced. Clinical trial data and product information emphasize dose changes as the typical times for symptoms. (novonordisk.ca)

Weeks 12–16 and beyond (stabilization or continuing escalation) - Many patients reach a maintenance dose by ~12–16 weeks and report gradual improvement in GI side effects, though some symptoms (notably constipation) may persist longer in some people. Trial reports provide median symptom durations (for semaglutide in some datasets: median nausea ~8 days, vomiting ~2 days, diarrhea ~3 days; constipation can last longer), and labels note GI events frequently resolve or diminish with continued treatment. If side effects are not tolerable, clinicians may hold at a lower dose or slow the titration. (rxreasoner.com)

Practical, evidence‑based strategies to manage common side effects - Nausea and vomiting - Eat small, frequent meals; avoid high‑fat or greasy foods; take liquids between meals rather than with meals. Ginger or peppermint may help. Discuss short courses of prescription antiemetics only with your clinician — they can be useful but should not mask severe warning signs. If nausea is severe or uncontrolled, your provider may pause dose escalation or reduce the dose. (doi.org) - Early satiety / reduced appetite - Plan nutrient‑dense small meals and protein at breakfast to maintain nutrition as appetite changes. Work with a dietitian when possible. (doi.org) - Constipation - Increase fluids, dietary fiber, and regular physical activity. Over‑the‑counter options include osmotic laxatives (eg, polyethylene glycol 3350). Multisociety and primary care guidance suggest prophylactic or early laxative use in at‑risk patients and stepwise management for persistent constipation. (aafp.org) - Diarrhea - Hydration is critical. For brief, nonsevere episodes consider dietary adjustments and loperamide if recommended by your clinician. Prolonged diarrhea risks dehydration and kidney stress. (doi.org) - Fatigue, dizziness, headache - Often transient; ensure hydration and adequate salt/calorie intake, especially if nausea reduces food intake. Discuss persistent symptoms with your clinician. (accessdata.fda.gov)

When to slow, pause, or stop dose escalation - If nausea/vomiting prevents eating for more than 24–48 hours, or you are losing weight too quickly or becoming dehydrated, pause escalation and contact your provider. Clinical trials allowed extended time on a dose (even up to 8 weeks) to permit GI symptoms to resolve; many guidelines recommend individualized slower titration if needed. (doi.org)

Red flags — when to seek urgent medical care Contact emergency services or go to the emergency room if you experience any of the following: - Severe or persistent abdominal pain, especially pain that radiates to the back, or pain that is constant and worse after eating — these are classic signs of acute pancreatitis. The FDA labels note cases of pancreatitis have been reported and advise prompt evaluation. (dailymed.nlm.nih.gov)
- High fever, rigors, or severe right‑upper‑quadrant pain, because GLP‑1s are associated with increased risk of gallbladder events (eg, gallstones or cholecystitis). Rapid, substantial weight loss can also increase gallstone risk. (accessdata.fda.gov)
- Severe dehydration (lightheadedness, fainting, very low urine output) or worsening kidney function — prolonged vomiting or diarrhea can precipitate acute kidney injury. (accessdata.fda.gov)
- Signs of severe allergic reaction: widespread rash, swelling of face/throat, difficulty breathing — stop the drug and seek emergency care. (accessdata.fda.gov)
- If you have diabetes and are taking insulin or sulfonylureas: symptoms of hypoglycemia (sweating, trembling, confusion, loss of consciousness) require immediate attention and glucose administration per your diabetes plan. GLP‑1s can increase hypoglycemia risk when used with insulin‑secreting agents unless those medications are adjusted. (rsc.niaid.nih.gov)

Special safety considerations (important) - Thyroid C‑cell tumor risk: rodent data show thyroid C‑cell tumors with these agents, so products carry warnings and are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Discuss personal/family history with your provider before starting. (accessdata.fda.gov)
- Gallbladder and pancreatitis risks: both are called out in product labeling and trial reports; monitor for the red‑flag symptoms above. (accessdata.fda.gov)
- Kidney injury via dehydration: prolonged vomiting or diarrhea can worsen kidney function; stay hydrated and notify your clinician if you have kidney disease. (accessdata.fda.gov)

Putting this into a simple week‑by‑week plan you can follow - Week 0 (before start): review health history, learn injection technique, plan for dose changes, stock oral rehydration/BRAT‑type foods, and agree with your clinician on red‑flag instructions and how quickly you’ll escalate. (accessdata.fda.gov)
- Weeks 1–4 (0.25 mg semaglutide / 2.5 mg tirzepatide start): expect nausea for several days to a week in many patients. Use small meals, avoid fatty foods, maintain hydration, and contact your prescriber for persistent vomiting. (rxreasoner.com)
- Weeks 5–12 (each dose increase): anticipate a transient return of symptoms around each dose change. If tolerable, continue; if not, slow the titration and consider short symptomatic treatments with clinician guidance. (novonordisk.ca)
- Week 16+: if you’ve reached the maintenance dose and symptoms persist beyond what you can manage with lifestyle measures, work with your clinician to consider dose reduction, longer intervals at a lower dose, supportive meds, or alternative therapies. (doi.org)

Conclusion GLP‑1 and GIP/GLP‑1 therapies can produce strong benefits for weight and glycemic control, but most people will have transient GI side effects clustered around initiation and dose increases. Plan ahead with your prescriber, use conservative dietary and hydration strategies, consider short, clinician‑directed symptomatic medication when needed, and be ready to pause or slow titration if side effects are severe. Seek urgent care for constant severe abdominal pain, signs of gallbladder issues, severe dehydration or kidney problems, allergic reaction, or hypoglycemia when on insulin or insulin‑secretagogues. With good planning and communication, many people tolerate escalation and reach maintenance doses safely. (accessdata.fda.gov)

References and resources (selected) - Ozempic (semaglutide) and Wegovy (semaglutide) FDA prescribing information / DailyMed. (dailymed.nlm.nih.gov)
- ZEPBOUND (tirzepatide) prescribing information / DailyMed. (dailymed.nlm.nih.gov)
- StatPearls / NCBI: Semaglutide adverse effects summary. (ncbi.nlm.nih.gov)
- Joint advisory: Nutritional priorities to support GLP‑1 therapy (2025) — practical strategies and guidance on titration and GI management. (doi.org)
- AAFP / expert guidance on managing GLP‑1 associated constipation (2026). (aafp.org)

If you’d like, I can turn this into a printable one‑page checklist you can use when you start your medication (pre‑start items, week‑by‑week quick actions, and red‑flag steps). Which drug and dose schedule are you starting, or considering?